Radioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsis — RADIOSA

Oligometastatic Prostate Cancer Clinical Trial

Official title:
Radioablation +/- Hormonotherapy for Prostate Cancer Oligorecurrences (RADIOSA Trial): Potential of Imaging and Biology

Status Recruiting

Clinical Trial Summary

A randomized phase II clinical trial (RADIOSA trial: Radioablation with or without Androgen DeprIvation therapy in metachronous prostate cancer OligometaStAsis). The aim is to compare time to progression between the two study arms: SBRT only or SBRT and hormonotherapy (ADT). The primary objective is to compare the progression-free survival (PFS) defined as the absence of new metastatic lesions (local, regional or distant) between the two arms. The secondary endpoints include the comparison of overall survival (OS), biochemical progression-free survival (BPFS), ADT-free survival, local control, treatment-induced acute and late toxicity, time to castration-resistant disease and QoL between the two arms; the development of a dedicated biobanking (collection of plasma and serum) for further biological investigation of predictive/diagnostic factors for personalized treatment; the preliminary evaluation of prognostic biomarkers; the correlation between imaging-derived parameters and treatment outcome.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03940235
Study type	Interventional
Source	European Institute of Oncology
Contact	Barbara A Jereczek-Fossa, Prof
Phone	+39 0257489037
Email	barbara.jereczek@ieo.it
Status	Recruiting
Phase	Phase 2
Start date	October 1, 2019
Completion date	April 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01859221` - Radiotherapy for Oligometastatic Prostate Cancer	N/A
Recruiting	`NCT06060652` - Prostate Oligometastatic Cancer Management Driven by Disease Biology et/or Immunoactivity (PROMETEO)
Recruiting	`NCT04610372` - 5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)	N/A
Recruiting	`NCT05915442` - Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer	Phase 2
Active, not recruiting	`NCT04992026` - The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer	Phase 2
Recruiting	`NCT05560659` - Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy	Phase 2
Completed	`NCT02192788` - Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer	N/A
Recruiting	`NCT06387056` - Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)	Phase 2